Latest ExpreS2ion Biotechnologies News & Updates

See the latest news and media coverage for ExpreS2ion. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
ExpreS2ion Biotechnologies (ExpreS2ion)

Clinical-stage immunotherapy biotechnology company

expres2ionbio.com
Headquarters
Horsholm, Denmark
Founded year
2010
Company type
Public company
Number of employees
20–50
Industry
Pharmaceuticals

Last updated

Latest news about ExpreS2ion Biotechnologies (ExpreS2ion)

In short: ExpreS2ion reported clinical progress for its breast cancer vaccine ES2B-C001 and completed a SEK 31.8 million rights issue in 2026.

Company announcements

ExpreS2ion

ExpreS2ion reviews Q1 progress across clinical, operational, financial fronts

CEO presented at BioStock Global Forum and Q1 results webcast; rights issue raised SEK 31.8 million.

Unlock all announcements with a

Media coverage

Investing.com

EXPRS2 Share News Today

ExpreS2ion Biotechnologies reported a 36% year-over-year increase in total income for the third quarter of 2025. The company also...

TradingView

ExpreS2ion reports consistent, durable anti-HER2 responses; advances ES2B-C001 Phase I after independent DSMB review — TradingView News

Hørsholm, Denmark, 25 March 2026 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion"), a clinical-stage biotechnology company with a focused pipeline of active...

Unlock all articles with a

Never miss news about ExpreS2ion

Track ExpreS2ion and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

ExpreS2ion competitors & trending companies

Browse news for competitors to ExpreS2ion and other trending companies.